<div>POI Summer 2025 blog
</div>
<div><br />
</div>
<div>Dear Friends, 
</div>
<div><br />
</div>
<div>Preventive Oncology International, Inc. (POI) was established in 1997, and became the international research arm of the Division of Gynecologic Oncology in the Department of Gynecology and Obstetrics at The Cleveland Clinic in Cleveland, Ohio. On the 29th of July 2008, with my retirement from clinical practice at the Cleveland Clinic, POI became its own 501(c)3. 
</div>
<div><br />
</div>
<div>To date POI has conducted research in China, Malaysia, Mexico, Peru, USA, Dominican Republic and collaborated with research groups working in India, Haiti, Kenya, Brazil, The Netherlands, Belgium, and the USA.
</div>
<div><br />
</div>
<div>POI has followed a few consistent guiding principles: 
</div>
<div>1.	To blend clinical care with our research, particularly in medically underserved communities.
</div>
<div>2.	To have a POI staff on site but to primarily work with an “in-country” research team plus local (community) caregivers. 
</div>
<div>3.	Conduct only investigator initiated (designed) clinical trials.
</div>
<div>4.	To always provide opportunities for students to join our teams for personal experience and in pursuit of advanced degrees.
</div>
<div><br />
</div>
<div>Over the past 27 years we have worked with hundreds of physicians, nurses, clinical assistants, and graduate students; we are indebted to the many women and their families who have participated in our clinical investigations and genuinely hope they feel their participation provided value for their lives and they felt the respect and gratitude we had for them for joining in our work. 
</div>
<div>The overwhelming feeling from our more than a quarter century of work was experienced the first time we entered a rural village and realized: the only reason the women were going to receive medical care was “because we were there”.
</div>
<div><br />
</div>
<div>Our major accomplishments (published, as of now, in 148 peer-reviewed manuscripts):
</div>
<div>1.	The introduction of HPV testing and liquid based cytology into China
</div>
<div>2.	The defining of how a self-collected specimen for HPV could be as sensitive as a physician obtained direct cervical sample for cervical cancer screening.
</div>
<div>3.	The first large (10,000 participants) randomized prospective trial of HPV self-collection with clinical endpoints that demonstrated the equivalent sensitivity of self and physician collected specimens for the detection of high-grade cervical pre-cancer and cancer.
</div>
<div>4.	The demonstration that the self-collection device is secondary in self-collection to processing the specimens with PCR (polymerase chain reaction) laboratory technologies.
</div>
<div>5.	Multiple studies on patient acceptance of self-collection in multiple cultures
</div>
<div>6.	Studies of specimen transport modalities culminating in simple dry brush transport
</div>
<div>7.	Developing community based and internet-based screening models
</div>
<div>8.	Demonstrating the inaccuracy of visual diagnostic methodologies (VIA/Colposcopy)
</div>
<div>9.	Collaborating in the development of the first HPV assay using next generation genomic sequencing
</div>
<div>10.	Providing care in our trials and the implementation that followed for hundreds of thousands of women with technologies that we were involved in their development and investigation.
</div>
<div><br />
</div>
<div>Then in 2025 the “newly elected” begin an assault on international aid programs and science. Caught up in this web of “government efficiency” were some of our countries most seasoned and accomplished scientists. The National Institutes of Health, our nation’s premier home for quality science and adjudicated funding was not spared. One example was the PAVE consortium (Papillomavirus Automated (A.I.) Visual Evaluation). PAVE is a novel strategy for cervical cancer screening and prevention targeting low-income and hard to reach populations. It integrates self-collection for the human papillomavirus and A.I. assisted visual evaluation to provide a risk of having high grade cervical pre-cancer or cancer. . PAVE’s current accomplishments include bringing together personnel from 4 continents (9 countries plus the USA) to achieve the goal of preventing cervical cancer globally.  The personnel include epidemiologists, physicians, statisticians, public health specialists, laboratory scientists, AI specialists, and engineers focused on working together to address the fact that 600,000 women develop cervical cancer every year, and 300,000 die from the disease. The women who are most at risk are those who were born before the HPV vaccine was available, were unable to get the vaccine prior to infection, or have no access to the vaccine.  Over the past 7 years using the latest developments in Human Papillomavirus technologies (in part developed by PAVE) and AI assisted visual examination (refined by PAVE), a novel low cost highly accurate screening strategy has been developed for resource-limited settings. Now with the finish line in site, the NIH funding has been eliminated as of June 2025. To complete the work the algorithm needs to be validated against current models and their cost-effectiveness demonstrated so world-wide acceptance and implementation can occur. 
</div>
<div>So now POI is energized and charged with a new mission. Do everything in our power to support our colleagues and help facilitate the completion of their work which is expected to require 2.5 years. 
</div>
<div>POI has now received a significant contribution that will support PAVE for the next 6 months. POI will continue to seek funding to support our own work, which will focus on PAVE, as well as the integration of data from future international and potential US sites. The studies are intended to demonstrate replicability of the new AI module on IRIS devices (camera) across different field sites, to assess the agreement between provider management decisions and the new model generated risk estimates, and to evaluate the acceptability of the new strategy through provider and patient feedback as well as examining the real costs of implementation. 
</div>
<div><br />
</div>
<div>We are proud as an organization to be able to integrate our work and help PAVE continue for the women of the world. As the saying goes “life happens when you are making plans”. POI has new life, and we hope you will support us.
</div>
<div><br />
</div>
<div>Warmest wishes,
</div>
<div>Jerry
</div>
<div><br />
</div>
<div>Jerome L. Belinson, M.D.
</div>
<div>President, Preventive Oncology International, Inc.
</div>
<div>Clinical Professor in the Department of Ob/Gyn &amp; Reproductive Biology
</div>
<div>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
</div>
<div>www.poiinc.org
</div>
<div><br />
</div>
<div><br />
</div>

Anonymous

Help Preventive Oncology International and PAVE do good work

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

currencyCode

Money Box Donation List Prompt Experiment Audience

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

NPO upsell education category

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

NPO recommendations prod

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

categoryGroup

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

NPO upsell animals category

NPO upsell disaster relief category

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

NPO upsell essential needs category

NPO upsell medical category

userCurrencyCode

Localized Currency

NPO upsell cancer category

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Help Preventive Oncology International and PAVE do good work

Still $2,700,000 to go. Help us build momentum.